XML 78 R66.htm IDEA: XBRL DOCUMENT v3.24.1.u1
REVENUE (Details)
$ in Thousands, € in Millions
1 Months Ended 3 Months Ended
Jan. 03, 2023
USD ($)
item
Jan. 03, 2023
EUR (€)
item
Jan. 31, 2023
USD ($)
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Jan. 03, 2023
EUR (€)
Revenue              
Total revenue       $ 190 $ 10,660    
Deferred revenue       477   $ 667  
License              
Revenue              
Total revenue         10,660    
Research and development services              
Revenue              
Total revenue       190      
License and Supply Agreement | Advanz Pharma              
Revenue              
Upfront payment received $ 10,700 € 10.0 $ 10,700        
Potential milestone payments to be received $ 142,200           € 134.0
Royalties as a percent of sales 20.00%           20.00%
Initial term 10 years 10 years          
Royalties as a percent of sales following initial term 10.00%           10.00%
Number of performance obligations | item 3 3          
License and Supply Agreement | Advanz Pharma | License              
Revenue              
Amount of performance obligation           9,300  
Total revenue         $ 10,700    
License and Supply Agreement | Advanz Pharma | Research and development services              
Revenue              
Amount of performance obligation           1,300  
Total revenue       200      
Deferred revenue       400   500  
License and Supply Agreement | Advanz Pharma | Manufacturing and supply material right              
Revenue              
Amount of performance obligation           100  
Deferred revenue       $ 100   $ 100